On February 9, 2022 Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, reported that it will host a virtual R&D Day at 10:00 am – 1:30 pm ET / 7:00 – 10:30 am PT on Wednesday, February 23, 2022 (Press release, Poseida Therapeutics, FEB 9, 2022, View Source [SID1234607916]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Poseida to host second annual Virtual R&D Day on February 23, 2022. $PSTX
Poseida’s second annual R&D Day will include presentations from the Company’s executive leadership, researchers, clinical team members, and key opinion leaders, followed by an interactive Q&A session. The event will focus on the Company’s differentiated genetic engineering platform technologies, novel approach to cell and gene therapy, and emerging discovery programs. Speakers will also discuss the Company’s R&D progress and its program and pipeline goals for 2022 in both cell and gene therapy, including its recently announced research collaboration with Takeda Pharmaceutical Company Limited ("Takeda") to develop non-viral in vivo gene therapies.
External speakers will include Susan F. Slovin, M.D., Ph.D., Associate Vice Chair of Academic Administration at Memorial Sloan Kettering Cancer Center and an investigator on a Phase 1 trial evaluating P-PSMA-101, the Company’s autologous CAR-T candidate for the treatment of metastatic castrate resistant prostate cancer (mCRPC); and Luca Gattinoni, M.D., Director of the Division of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy at the University of Regensburg in Germany. Dr. Gattinoni is a member of the Company’s Immuno-Oncology Scientific Advisory Board.
Registration for this virtual event and access to the live webcast will be available on the Investors & Media section of Poseida’s website, www.poseida.com. A replay of the webcast will be available for 30 days following the presentation.